Tags |
|
|
Answers - Agency CMO PO Bonds Trading
Question:
My traders continue to overpay for PO bonds. Could you please let me know the variables to use when pricing and trading a PO bond?
Answer:
There are different types of PO bonds, such as PA
My traders continue to overpay for PO bonds. Could you please let me know the variables to use when pricing and trading a PO bond?
Answer:
There are different types of PO bonds, such as PA
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
C, TAC, SC, SEQ, PT, STP SUP, PO or Remics, etc.
You must take the following factors into consideration before submitting a bid or asking for a PO bond:
The uncertainty of loan payments due to poor docu
You must take the following factors into consideration before submitting a bid or asking for a PO bond:
The uncertainty of loan payments due to poor docu
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
entation and human error;
Proper hedging instrument;
The number of hedging contracts that you need;
Costs of hedging;
Option;
Past cash flow;
Scaling up prepayment mode
Proper hedging instrument;
The number of hedging contracts that you need;
Costs of hedging;
Option;
Past cash flow;
Scaling up prepayment mode
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ls vectoring out the PSA/CPR with emphasis on key attributes, modified duration, effective duration, average life and convexity using YB, Bloomberg or INTEX;
Forecasting payments given inflation, mortgag
Forecasting payments given inflation, mortgag
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
services fees and loan balances;
Is the collateral backed by GNMA, FNMA, FHLMC or a private label (whole loan CMO)?
PO(A) PO(B) PO(C)
PSA: 90%
Is the collateral backed by GNMA, FNMA, FHLMC or a private label (whole loan CMO)?
PO(A) PO(B) PO(C)
PSA: 90%
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
Base 110%
CPN WAVG: 5.94 8.9 5.60
CPN SDEV: 0.12 0.10 0.11
MAT WAVG:
CPN WAVG: 5.94 8.9 5.60
CPN SDEV: 0.12 0.10 0.11
MAT WAVG:
ucts have become life saving products for the pharmaceutical companies who doesnt have many innovative molecules in their product pipeline and have been inc
07 311 300
Figure 1:
PO (A) PO(B) PO(C)
Effective Duration: 11.4 20.0 10.50
The PO with 20.0 effective duration is
Figure 1:
PO (A) PO(B) PO(C)
Effective Duration: 11.4 20.0 10.50
The PO with 20.0 effective duration is
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
the most volatile, so when you bid/ask you need to know the correct OAS and the forward yields curve, as you can see from Figure 1 above. The correct way to look at Figure 1 is that as a prop trader this PO ass
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
t class will appreciate or lose 11 to 20% in the event of a 100bps in yield change.
As a prop trader you want to shock the cash flow and duration; this gives you an idea of where to bid. The goal is to avoid o
As a prop trader you want to shock the cash flow and duration; this gives you an idea of where to bid. The goal is to avoid o
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
verpaying for a bond and to avoid losing out on a bid.
PO(A) PO(B) PO(C)
Duration: 4.0 8.6 3.49
A prop trader should quantify the exposure of t
PO(A) PO(B) PO(C)
Duration: 4.0 8.6 3.49
A prop trader should quantify the exposure of t
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
e prepayment models risk with emphasis on the PSA if the deal is new and CPR if the deal is a seasoned one. Bear in mind that major broker dealers have their own matrix; it is imperative that you use public inf
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
rmation in analyzing the price that you want to pay for a bond. After all, Long Term Capital Management had its own matrix and the model failed.
The transparency and flexibility of your prepayment model should
The transparency and flexibility of your prepayment model should
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
allow the trader to modify the parameters to reflect your PSA/CPR expectations.
In trading agency CMO PO you should remember that the PO depreciates in a rising rates environment and appreciates in a low rate
In trading agency CMO PO you should remember that the PO depreciates in a rising rates environment and appreciates in a low rate
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
environment. You goal is to be able to tell when to bid either using OAS or forward yield curve. When bidding for a new issue it is imperative to remember that the value of your PO will depreciate due to amorti
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
zation, and discount value factors because the original principle decreases every month. I have priced over a thousand of PO (SUP, TAC, PT, STP, PAC, SEQ and REMICS); these bonds are not all equal. Remember tha
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
the OAS is not the be all and end all variable; other variables such as the effective duration, LTV, FICO scores and geographic analysis are as vital.
The best thing for a hedge fund manager to do is to visit
The best thing for a hedge fund manager to do is to visit
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
an underwriter with his/her own coupon formula. Place an order instead of waiting for the underwriter to sell you some PO nobody wants to buy, and then get a promise that the value of your PO will not go down.
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
I know and have seen structures that were extremely profitable and remained so! The game of PO trading is like Las Vegas: the house never loses. You just need a seasoned trader who can go toe to toe with the ho
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
use and come out on top.
Always remember there are times to buy and sell PO. The question is, do you know the right time? And can you value PO within minutes and place a bid/ask price if you have to?
In concl
Always remember there are times to buy and sell PO. The question is, do you know the right time? And can you value PO within minutes and place a bid/ask price if you have to?
In concl
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
sion, an agency CMO prop trader needs to have an assumption based on the historical volatility vis-?-vis effective duration, modified duration, and how speed (PSA/CPR), in addition to knowing the VaR of each PO
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.answers.org.ua/article/102156/answers-Agency-CMO-PO-Bonds-Trading.html">Agency CMO PO Bonds Trading</a>
BB link (for phorums):
[url=http://www.answers.org.ua/article/102156/answers-Agency-CMO-PO-Bonds-Trading.html]Agency CMO PO Bonds Trading[/url]
Related Articles:
Translator Prerequisites and the A-Z of Becoming a Translator
Bookmark it:
|